2026 Sponsors

Immunai's engineering-first platform maps the immune system for the discovery and augmentation of novel therapeutics, through single-cell sequencing, functional genomics, big data and ML. Immunai holds a successful track record of partnering with leading pharmaceutical and biotech companies, academic institutions and hospitals to optimize their preclinical and clinical decision-making. To learn more, please visit https://www.immunai.com/

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans. For more information, go to https://onc.ai/

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. For more information, go to www.td2inc.com

MERIT is an oncology endpoint expert providing image collection, centralized reading, and data management services for clinical trials since 2012. We have supported hundreds of trials across 58 countries. MERIT partners with CROs as well as pharma and biotech companies to deliver reliable endpoint services in global clinical trials. To learn more, please visit meritcro.com

Nona Biosciences specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

Ozette is a biotechnology company pioneering vertically integrated and computationally-driven solutions for deep immune profiling. By combining advanced AI-driven analysis with high quality & high-dimensional single-cell data generation in our Laboratory, Ozette is transforming immunological insights into actionable knowledge, empowering biopharmaceutical companies to develop precision therapies for complex diseases.

For more information, please visit https://www.ozette.com/

RadMD is a full service, global imaging core lab for Phase 1-Phase 3.  Our oncology focus means expert, responsive teams who move quickly and are adaptable to your program.   Our industry leading reader group, managed by  medical & scientific affairs team continues to set higher standards for quality and innovation to meet demands of clinical development today. For more information, visit https://radmdimaging.com/

MedQIA, WorldCare Clinical and DARC, have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s unique AI-based software platform integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. For more information, go to https://www.voiantclinical.com/

Picture Health creates multimodal AI biomarkers for precision oncology via our proprietary Px Platform with next-generation radiomics capabilities.  Our advanced radiomic and pathomic imaging features, demonstrated in over 80 peer reviewed papers, are tied to interpretable biological tumor characteristics. Picture Health partners with biopharma companies to improve patient characterization & selection using small datasets from Phase 1 and 2 clinical trials. The Px Platform enables us to develop custom predictive AI biomarkers tailored to a specific indication. For more information, go to https://picturehealth.com/

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information, go to www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/